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Background: Self-report is commonly used as a source of information on the use of medicine. The aim of this
study was to investigate the relationship between self-reported and register-based information on the use of
psychoactive medication, especially in respect to antidepressants, and reasons of non-reporting.
Methods: Study subjects (n = 11,031) originated from a population-based cohort of postmenopausal women born
in 1932–41 from Eastern Finland who responded to a postal enquiry in 1999. Self-reported currently used
prescribed medications were compared to the National prescription register data. Diuretics served as a reference for
psychoactive medications.
Results: Only 44% out of 1,638 women reported their use of psychoactive medication when compared to the
prescription register within a 4-month time window preceding their response to enquiry. Altogether, 55% out of
777 women reported their use of antidepressants and 29% out of 861 reported their use of other psychoactive
medications. In comparison 83% reported their use of diuretics. After excluding the occasional use, an increase in
sensitivity by approximately 10 percentage points was seen regardless of the group of psychoactive medication.
High use and history of work disability pension due to psychiatric cause were associated with a much higher
likelihood of reporting psychoactive medication use (for antidepressants 70% and 81%, respectively).
Conclusions: For research purposes, self-reported current use of psychoactive medication seems to be a sufficient
indicator for regular use of antidepressants or in respect of use of any psychoactive medication, for subjects with
severe psychiatric disease.
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Self-report is commonly used as a source for informa-
tion regarding medication exposure in epidemiological
studies. This type of data is dependent on memory and
maybe vulnerable to recall bias, but also unwillingness
to report may play a role. Thus, for valid results, accur-
ate information or at least knowledge of the degree of
misreports is needed. The validity of self-reported medi-
cation use can be assessed by comparing self-reports to* Correspondence: pr.rauma@gmail.com
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reproduction in any medium, provided the orother data sources such as pharmacy data or medical re-
cords. Previous studies have investigated several different
groups of medications [1-10]. For example, Klungel
et al. [10] reported that approximately 70% of all medi-
cations currently used by patients with hypertension
were correctly recalled in a self-administered question-
naire. However, the validity of self-reports has been
found to vary extensively according to the type of medi-
cation taken [9,11-13]. The use of psychoactive medica-
tion has been shown to be less accurately reported than
other medications [9,11,13].
Depression is one of the leading causes of disease bur-
den in the world and a major public health problem also
among the elderly [14]. The occurrence of depression isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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after menopause [15]. There is limited validation data fo-
cusing solely [16-19] or among others [9,11-13,20-22] on
the use of antidepressants or other psychoactive agents.
Especially large cohort studies are rare [13,22]. Only few
studies have investigated factors affecting accuracy of
self-reported use of these medications [16,22]. Thus,
more knowledge is needed regarding the extent and
reasons associated with non-reporting of psychoactive
medications, which could serve as a guide for future
research.
The aim of the present study is to investigate among
postmenopausal women from Eastern Finland, the
agreement between self-reported use and registry-based
data on purchased psychoactive medications, with par-
ticular reference to antidepressants. The causes for non-
reports will also be investigated.
Methods
Study design and subjects
The study population (n = 11,031) for this cross-
sectional population-based study was formed as follows:
in 1989, a baseline postal enquiry was sent to all the
14,220 female residents born in 1932–41 of Kuopio
Province, Finland (OSTPRE Study) [23,24]. The 10-year
follow-up enquiry in 1999 was sent to 12,562 women
alive and with known address out of the 13,100 baseline
respondents. This enquiry was returned by 11,537
women. Out of these 11,537 women, 11,031 women
responded to the question determining current medica-
tion usage in 1999. The study has been approved by the
ethics committee of Kuopio University Hospital. In-
formed consent of the study subjects was obtained by
postal enquiry.
Questionnaire data
The study questionnaire included questions on marital
status, residency (rural/city), height, weight, number of
chronic health disorders, number of prescribed medica-
tions, use of hormone therapy (HT) (no/yes), life satis-
faction (LS), physical activity (hours per week), smoking
(no/yes) and consumption of beer, wine and distilled al-
coholic beverages. The total use of alcohol was com-
puted as grams (12 g/drink) per month and categorized
(none/<360 g/≥360 g). Body mass index (BMI) was
calculated as weight (kg)/height (m) squared and catego-
rized (<25/25-29/≥30 kg/m2). LS was measured with a
4-item scale (range 4–20) [25-29]. It was used as a 3-
category variable: 4–6 (satisfied), 7–11 (intermediate)
and 12–20 (dissatisfied) based on the standard deviation
of the mean [27]. Education (4-category) was asked on a
subsample (n = 3,222) who underwent bone densitom-
etry. All these factors were tested as covariates in multi-
variate analyses.Participants were asked current medication usage:
“Are you at the moment under medication prescribed
by a doctor? Specify the names of the medications.”
The reported medications were coded according to the
Anatomical Therapeutic Chemical (ATC) code [30].
The ATC-categories investigated in the present study
were: any psychoactive medications (N05, N06), antide-
pressants (N06A, N06CA) (with or without using other
psychoactive medications) and other psychoactive medi-
cations (N05, N06B, N06CB, N06D) (without using anti-
depressants). In addition, “sole use of antidepressants”
was also investigated. Purchasing of anti-dementia drugs
(ATC: N06D) or psychostimulants/nootropics (N06B)
during 2000–2005 according to National prescription regis-
ter was used as memory variable (no/yes). Diuretics (C03),
which are an independent, usual and regularly used medi-
cation group, were chosen to serve as a reference for psy-
choactive medications. Diuretics were used as follows: 1)
any use (in tables), 2) together with psychoactive medica-
tion and 3) without psychoactive medication.Register data
The study questionnaire data was linked with the
National prescription register and the National
Register for Work Disability Pensions by personal
identification codes. The prescription register from
the Social Insurance Institution of Finland (KELA)
contains data regarding all reimbursed prescription
medicines purchased in any pharmacy in Finland. It
does not include information on 1) medication use
in hospitals or community nursing homes, where
medicines are included in the services; 2) medica-
tions which are not reimbursable such as small pack-
ages costing under a fixed deductible share (i.e. 8.41
€ in 1999) unless being a specially refunded medi-
cine due to the selected chronic diseases including
psychosis [31]. The defined daily doses (DDD) for
medical products have been obtained from the
Finnish Medicines Agency (FIMEA).
History of work disability pension up to the year 1996
(no/due to somatic cause/due to psychiatric cause) and
medications purchased from a pharmacy within four or
within 12 months before response to the enquiry in
1999 as DDD tertiles were used in the analysis. In
Finland, only 3 months’ refunded medication can be
purchased from pharmacy at a time. Thus, a 4-month
time window preceding the date of response to enquiry
was chosen for prescription register data to ensure that
a person would purchase a medication at least once (if
used continuously) [19]. In order to explore the agree-
ment of self-report, also a 12-month time window pre-
ceding the enquiry and a 4-month time window after the
enquiry were applied. For loss analysis, the index date
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the date the questionnaire was sent.
Statistical analyses
Statistical analyses were performed using the SPSS stat-
istical package 17.0 for Windows (SPSS Inc., Chicago,
IL, USA). Differences between study groups were
examined with the Chi-squared test and the t-test for
independent groups, or, in the case of variables not
following a normal distribution, the non-parametric
Mann–Whitney U-test. Agreement between the self-
reported use and the National prescription register data
as the golden standard were analyzed with sensitivity
(i.e. recall rate or accuracy), specificity and Kappa-
values (overall agreement).
To study factors affecting agreement of self-report
and register data, logistic regression models were used.
Only those women who according to the prescription
register had purchased antidepressants or psychoactive
medications were selected. Self-report (no/yes) was the
outcome measure (i.e. dependent variable). Multivariate
analysis was used to assess the independent effect of
certain personal and health-related factors. Covariates
were chosen into models if they were significantly asso-
ciated with outcome. In the multivariate model 1, age,
marital status, BMI, alcohol consumption and LS were
covariates. In model 2, additional covariates included
history of work disability pension up to the year 1996
and number of self-reported prescribed medications as
well as amount of purchased psychoactive medications
from the prescription register.
Results
Characteristics
According to the prescription register, 1,638 (14.8%) of
the 11,031 participants, had purchased psychoactive
medications during the four months preceding the self-
report. A total of 777 (7.0%) women had purchased anti-
depressants with or without other psychoactive medica-
tions, while 861 (7.8%) had purchased other psychoactive
medications than antidepressants. Out of the 777 anti-
depressant users, 393 (3.6%) were “sole antidepressant
users”, while 384 women also used other psychoactive
medications. Among these 384 women, antipsychotics
were used by 123 women, anxiolytics by 198 women and
hypnotics or sedatives by 184 women. In the entire group
of users of other psychoactive medications (n = 861), anti-
psychotics were used by 147 women, anxiolytics by 315
and hypnotics or sedatives by 513 women. Users of psy-
choactive medications based on prescription register dif-
fered from non-users for all the study variables (Table 1).
Users had more diseases and were less satisfied with their
lives, while non-users were better off in terms of smoking
and BMI, but not in terms of alcohol use. Of the entirestudy population, 22.7% had a history of work disability
pension, this proportion being highest among users of an-
tidepressants (43.2%).
Sensitivity between self-reported and prescription
register data
Self-reported use of medication was compared to the
prescription register data within a 4-month time window
preceding the response to enquiry (Tables 2 and 3). The
sensitivity of self-reports was 44.2% for all psychoactive
medication. It was higher for use of antidepressants
(54.8%) than for use of other psychoactive medications
(29.0%). For sole antidepressants users, the proportion
was 50.1%. Altogether, 66 women reported use of antide-
pressants and 152 women reported use of any psycho-
active medication, though they had not purchased the
medication within the 4-month time window preceding
the self-report (Table 2). For the preceding 12 months
prior to the self-report, these figures were 12 and 40 per-
sons, respectively.
Self-reported use of diuretics covered a much higher
percentage (83.2%) of the register-based data than use of
psychoactive medication. Users of psychoactive medica-
tion also reported their use of diuretics less accurately
(76.0%) than non-users (85.1%) (P = 0.001).
The sensitivity in use of psychoactive medication be-
tween the two data sources was better when only regular
use was considered by taking into account medication
purchased within four months both before and after the
enquiry: the proportion of those reporting their use of
medication was, thus, 55% for all psychoactive medica-
tions and 65% for antidepressants.
The exclusion of the low use tertile (i.e. occasional/ir-
regular use) and the widening of the register data time
window improved the sensitivity between self-report and
register data. Thus, the sensitivity of self-reported regu-
lar use of antidepressants was 71.3%, if the medication
purchase precondition was four months before and after
the response to enquiry. The proportion of false positive
self-reports decreased from 13.4 to 2.5%, if the time win-
dow was widened from 4 to 12 months before the re-
sponse to enquiry.
Sensitivity and specificity of self-reports were 0.44 and
0.98 respectively, for psychoactive medication and 0.83
and 0.98 respectively for diuretics (Table 2). Kappa-
values were 0.53 for all psychoactive medication, 0.65 for
antidepressants, 0.30 for other psychoactive medications
and 0.82 for diuretics (all P < 0.001). Sensitivity of self-
reported psychoactive medication increased markedly
according to the amount of use (Table 3).
Factors affecting sensitivity of self-report
The amount of purchased psychoactive medications
(DDDs/four months), history of work disability pension



















Continuous mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)
Age (years) 62.3 (2.9) 62.2 (2.9) 62.5 (3.0)*** 62.3 (3.0) 62.7 (2.9)*** 62.9 (2.9)***
BMI (kg/m2) 27.6 (4.7) 27.5 (4.6) 28.3 (5.2)*** 28.4 (5.2)*** 28.2 (5.2)*** 30.5 (5.5)***
Number of prescribed
medications
2.1 (2.0) 1.8 (1.9) 3.3 (2.2)*** 3.5 (2.2)*** 3.1 (2.2)*** 4.0 (2.2)***
Number of diseases 2.4 (1.8) 2.3 (1.8) 3.2 (2.0)*** 3.2 (2.0)*** 3.2 (1.9)*** 3.5 (2.0)***
Self-rated LS a 8.1 (2.8) 7.9 (2.6) 9.4 (3.5)*** 9.9 (3.6)*** 9.0 (3.3)*** 8.5 (3.1)***
Categorical n (%) n (%) n (%) n (%) n (%) n (%)
Disability pension c 2,500 (22.7) 1,854 (19.7) 646 (39.5) *** 328 (43.2) *** 318 (36.9)*** 416 (33.3)***
HT use 2,405 (21.8) 2,010 (21.4) 395 (24.1)* 215 (27.7)*** 180 (20.9) 224 (17.9)***
Smoking 908 (8.2) 695 (7.4) 213 (13.0)*** 90 (11.6) *** 123 (14.3) *** 87 (7.0)
Use of alcohol 5,487 (51.4) 4,749 (52.1) 738 (47.0) *** 344 (46.3) ** 394 (47.6)* 540 (45.6)***
Abbreviations: BMI, body mass index; HT, hormone therapy; SD, standard deviation.
*P value < 0.05, **P < 0.005, ***P ≤ 0.001 difference from non-users.
a Self-rated life satisfaction, range 4 to 20, higher score indicating lower life satisfaction.
b The group includes all diuretics users.
c History of work disability pension up to 1996.
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reported prescribed medications as well as being unmar-
ried were strongly associated with higher sensitivity
between self-reported and register-based data regardless
of type of medication (Table 3). Among users of any psy-
choactive medication also life dissatisfaction and higher
BMI were associated with better sensitivity.
In multivariate models, greater alcohol consumption
was associated with lower sensitivity for use of antide-
pressants (odds ratios, ORmodel1 = 0.39, P = 0.045 and
ORmodel2 = 0.34, P = 0.043) (Table 4). In respect to mari-
tal status, those who are single had higher sensitivity
than others (Tables 4 and 5). Higher number of any self-Table 2 Comparison of self-reports and the National prescrip
diuretics
Self-reported
Any psychoactive medication Antidepressa
yes no yes no
Prescription register
Yes a 724 914 426 35




* P value < 0.001.
a Purchased the given medication within four months before response to postal en
b The group includes all diuretics users.reported prescribed medication, higher use of antide-
pressants or any psychoactive medication according to
prescription register and work disability pension due
to psychiatric cause (model 2) were all associated inde-
pendently with higher sensitivity, while work disability
pension due to somatic cause was associated with lower
sensitivity.
Among women using any psychoactive medication (n =
1,638) (Table 5), improved sensitivity between self-report
and register-based data was associated with younger age
(all models), but not with residence or physical activity
nor was it related to education in the sample of 3,222
women, or to registry-based data on subsequent use oftion register data for psychoactive medication and
nts Other psychoactive medication
without antidepressants
Diuretics b
yes no yes no
1 250 611 1,039 210





Table 3 Sensitivity (%) of self-reported psychoactive medication use by characteristics of study subjects compared to
the National prescription register data during the four months preceding the self-report
Use of psychoactive medication according to the National prescription data
Any Antidepressant Other
Characteristics % (n) P valuea % (n) P valuea % (n) P valuea
Self-reported use of psychoactive medication 44.2 (724/1,638) 54.8 (426/777) 29.0 (250/861)
Age (years) < 0.001 0.254 < 0.001
57 - 62 49.3 (429/871) 56.6 (248/438) 36.0 (156/433)
63 - 68 38.5 (295/767) 52.5 (178/339) 22.0 (94/428)
Marital status < 0.001 0.021 < 0.001
Single 64.3 (99/154) 70.0 (56/80) 47.3 (35/74)
Married / cohabitating 42.3 (413/977) 54.8 (251/458) 26.2 (136/519)
Divorced 50.0 (87/174) 51.7 (45/87) 40.2 (35/87)
Widoved 36.7 (114/311) 48.9 (69/141) 22.9 (39/170)
Body mass index (kg/m2) 0.011 0.195 0.115
< 25 41.1 (170/414) 50.8 (93/183) 27.7 (64/231)
25 – 29.99 42.1 (262/623) 54.4 (162/298) 27.1 (88/325)
≥ 30 49.8 (240/482) 59.6 (137/230) 34.5 (87/252)
Alcohol consumption (g/month) < 0.001 0.075 < 0.001
None 48.1 (400/832) 57.1 (228/399) 33.9 (147/433)
< 360 38.0 (264/695) 51.3 (164/320) 21.9 (82/375)
≥ 360 51.2 (22/43) 37.5 (9/24) 63.2 (12/19)
Number of self-reported diseases 0.911 0.365 0.670
0 45.9 (34/74) 44.4 (16/36) 34.2 (13/38)
1 − 2 43.4 (258/594) 53.5 (154/288) 29.1 (89/306)
≥ 3 44.0 (410/931) 56.1 (245/437) 27.7 (137/494)
Smoking 0.190 0.410 0.075
no 43.6 (621/1,425) 54.3 (373/687) 27.9 (206/738)
yes 48.4 (103/213) 58.9 (53/90) 35.8 (44/123)
HT use 0.727 0.872 0.357
no 44.0 (546/1,240) 55.2 (309/560) 29.9 (203/680)
yes 45.1 (178/395) 54.4 (118/217) 26.1 (47/180)
Life satisfaction 0.016 0.222 0.472
satisfied 42.5 (102/240) 63.0 (58/92) 25.6 (53/207)
intermediate 42.0 (402/958) 53.1 (229/431) 28.7 (142/494)
dissatisfied 50.1 (212/423) 54.9 (134/244) 31.4 (45/143)
Number of self-reported prescribed medication <0.001 <0.001 <0.001
0 0.0 (0/110) 0.0 (0/35) 0.0 (0/75)
1 − 2 34.2 (202/590) 40.8 (115/282) 24.4 (75/308)
≥ 3 55.7 (522/938) 67.6 (311/460) 36.6 (175/478)
Amount of purchased medication b < 0.001 < 0.001 < 0.001
low 23.4 (120/513) 35.4 (85/240) 12.9 (40/309)
moderate 42.5 (259/610) 56.8 (151/266) 39.6 (82/207)
high 67.0 (345/515) 70.1 (190/271) 37.1 (128/345)
History of work disability pension < 0.001 < 0.001 < 0.001
no 38.7 (384/992) 51.4 (231/449) 24.3 (132/543)
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Table 3 Sensitivity (%) of self-reported psychoactive medication use by characteristics of study subjects compared to
the National prescription register data during the four months preceding the self-report (Continued)
somatic cause 39.1 (181/463) 47.4 (99/209) 25.6 (65/254)
psychiatric cause 86.9 (159/183) 80.7 (96/119) 82.8 (53/64)
Abbreviations: HT, hormone therapy.
a P value from the chi-square test between the subgroups.
b Tertile cutoffs for amount of use (DDD/4 months): psychoactive medication <34 (low), 34–100 (moderate), >100 (high), antidepressants <33, 33–99.9, ≥100, other
psychoactive medication <33, 33–99.99, ≥100.
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the entire study population had purchased anti-dementia
medication in 2000–2005. Obesity was associated with
better sensitivity in the use of any psychoactive medicationTable 4 Factors related to the sensitivity of self-reported use
(n = 777) by logistic models
Univariate model
Variables OR 95% CI P value a
Age (years) 0.97 0.93, 1.02 0.241
Marital status
single 1.0
cohabitation / married 0.52 0.31, 0.87 0.012
divorced 0.46 0.24, 0.87 0.017
widoved 0.41 0.23, 0.73 0.003
Body mass index (kg/m2)
< 25 1.0
25-29 1.15 0.80, 1.67 0.450
≥ 30 1.43 0.96, 2.11 0.076
Alcohol consumption (g/month)
none 1.0
< 360 0.79 0.59, 1.06 0.115
≥ 360 0.45 0.19, 1.05 0.066
Life satisfaction
satisfied 1.0
intermediate 0.67 0.42, 1.06 0.084
dissatisfied 0.71 0.44, 1.17 0.180
Number of prescribed medications (continuous) 1.38 1.28, 1.49 < 0.001
Amount of purchased antidepressants b
low 1.0
moderate 2.39 1.67, 3.43 < 0.001
high 4.28 2.95, 6.20 < 0.001
History of work disability pension
no 1.0
somatic cause 0.85 0.61-1.18 0.330
psychiatric cause 3.94 2.41-6.44 < 0.001
Abbreviations: CI, confidence interval; OR, odds ratio.
a P value from the chi-square test.
b Tertile cutoffs for amount of use (DDD/4 months): <33 (low), 33–99.9 (moderate),
c Multivariate models include all the variables in the column.(model 1), but the inclusion of the number of self-
reported prescribed medications and history of work dis-
ability variables into the model totally abolished this asso-
ciation (Table 5).of antidepressants compared to register-based data
Multivariate model 1 c (n = 679) Multivariate model 2 c (n = 679)
OR 95% CI P value a OR 95% CI P value a
0.97 0.93, 1.03 0.329 0.97 0.92, 1.03 0.312
1.0 1.0
0.47 0.27, 0.81 0.007 0.58 0.32, 1.06 0.076
0.46 0.23, 0.92 0.029 0.52 0.24, 1.12 0.097
0.40 0.21, 0.76 0.005 0.53 0.26, 1.06 0.073
1.0 1.0
1.31 0.89, 1.93 0.168 1.14 0.74, 1.75 0.562
1.50 0.99, 2.25 0.054 0.87 0.55, 1.38 0.551
1.0 1.0
0.84 0.61, 1.16 0.287 0.91 0.64, 1.29 0.593
0.39 0.16, 0.98 0.045 0.34 0.12, 0.97 0.043
1.0 1.0
0.61 0.37, 1.01 0.054 0.70 0.41, 1.22 0.212
0.72 0.42, 1.24 0.235 0.74 0.41, 1.34 0.313
– 1.37 1.25, 1.50 < 0.001
– 1.0
– 2.56 1.68, 3.89 < 0.001
– 3.81 2.51, 5.79 < 0.001
– 1.0
– 0.63 0.42, 0.95 0.026
– 2.55 1.46, 4.46 0.001
≥100 (high).
Table 5 Factors related to the sensitivity of self-reported use of any psychoactive medication compared to register-
based data (n = 1,638) by logistic models
Univariate model Multivariate model 1 c
(n = 1,448)
Multivariate model 2 c
(n = 1,446)
Variables OR 95% CI P value a OR 95% CI P value a OR 95% CI P value a
Age (years) 0.93 0.90, 0.96 < 0.001 0.93 0.90, 0.97 < 0.001 0.94 0.91, 0.98 0.006
Marital status
single 1.0 1.0 1.0
cohabitation/married 0.41 0.29, 0.58 < 0.001 0.42 0.29, 0.62 < 0.001 0.48 0.31, 0.73 0.001
divorced 0.56 0.36, 0.87 0.009 0.55 0.34, 0.89 0.015 0.60 0.35, 1.03 0.064
widoved 0.32 0.22, 0.48 < 0.001 0.34 0.22, 0.53 < 0.001 0.38 0.23, 0.62 < 0.001
Body mass index (kg/m2)
< 25 1.0 1.0 1.0
25-29 1.04 0.81, 1.34 0.751 1.15 0.88, 1.49 0.317 1.00 0.74, 1.34 0.989
≥ 30 1.42 1.09, 1.86 0.009 1.46 1.11, 1.94 0.008 0.95 0.69, 1.31 0.770
Alcohol consumption (g/month)
none 1.0 1.0 1.0
< 360 0.74 0.58, 0.95 0.018 0.68 0.55, 0.85 0.001 0.80 0.63, 1.03 0.079
≥ 360 0.63 0.49, 0.81 < 0.000 0.87 0.45, 1.67 0.672 0.89 0.42, 1.87 0.749
Life satisfaction
satisfied 1.0 1.0 1.0
intermediate 0.98 0.74, 1.30 0.880 0.99 0.73, 1.35 0.954 1.04 0.73, 1.47 0.837
dissatisfied 1.36 1.00, 1.87 0.059 1.32 0.93, 1.87 0.118 1.20 0.81, 1.78 0.371
Number of prescribed medications (continuous) 1.34 1.27, 1.40 < 0.001 – 1.32 1.25, 1.40 < 0.001
Amount of purchased psychoactive medicationb
low 1.0 – 1.0
moderate 2.42 1.86, 3.13 < 0.001 – 1.85 1.38, 2.47 < 0.001
high 6.65 5.05, 8.75 < 0.001 – 4.12 3.04, 5.60 < 0.001
History of work disability pension
no 1.0 – 1.0
somatic cause 1.02 0.81, 1.27 0.889 – 0.66 0.50, 0.86 0.003
psychiatric cause 10.49 6.70, 16.42 < 0.001 – 6.53 3.90, 10.92 < 0.001
Abbreviations: CI, confidence interval; OR, odds ratio.
a P value from the chi-square test.
b Tertile cutoffs for amount of use (DDD/4 months): <34 (low), 34–100 (moderate), >100 (high).
c Multivariate models include all the variables in the column.
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sants use (n = 393), a greater number of any prescribed
medication (OR = 1.33, P < 0.001), amount of purchased
antidepressants (ORmoderate use = 2.89, P < 0.001 and ORhigh
use = 3.57, P < 0.001) and history of work disability due to
psychiatric cause (OR = 4.04, P = 0.002) remained correlates
of self-report in the multivariate model 2 (Cf. Table 4).
Loss analysis
According to the prescription register, the 1,025 women
who did not return the questionnaire, purchased (during
the four months preceding the follow-up enquiry in 1999)more often than the responders who reported any psycho-
active medication (23.3 vs. 14.8%, P < 0.001), antide-
pressants (9.3 vs. 7.0%, P = 0.010) or other psychoactive
medications (14.0 vs. 7.8%, P < 0.001). The correspond-
ing proportions, for the 506 women who returned the
questionnaire but did not answer the medication question
were similar with those of the responders (15.2, 6.3 and
8.9%, respectively). Correction of non-response to the en-
quiry or the medication question increased the population
estimate for use of any psychoactive medication from 14.8
to 15.5%, use of antidepressants from 7.0 to 7.2% and use
of other psychoactive medication from 7.8 to 8.4%.
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Postmenopausal women are at increased risk of depression.
This study investigated agreement between self-reported
use of psychoactive medication and the National prescrip-
tion register data and possible related factors among post-
menopausal women. The sensitivity of self-report was 44%
for any psychoactive medication and 55% for antidepres-
sants, while it was over 80% for diuretics. However, higher
use and history of work disability pension due to psychi-
atric cause increased sensitivity strongly.
Methodological differences such as selected golden
standard, interview vs. enquiry method or structure and
wording of questions might be reasons for the differ-
ences in the results between studies. Other Finnish stud-
ies have previously found high overall agreement (ad
0.87) for antidepressants [18,19] and antipsychotics
[18,19,22] with the same golden standard as in this
study. This agreement difference might be due to longer
purchase time window [18,22], younger population
[18,22] or the interview vs. enquiry method and pre-
scriptions brought to the interview [18,19]. A large study
by Nielsen et al. [13] with home interview but pharmacy
records as a reference, found self-report sensitivity of
antidepressant use (56%) similar to ours. Also Boudreau
et al. [9] found lower sensitivity for antidepressants (44-
66%) when using interview with specific medication
questions. However, higher sensitivities for self-report of
antidepressants and psychoactive medication (70-89%)
have generally been obtained with different methodolo-
gies; such as medical records [12] or physician-reported
data as golden standard [16], when asked “never/ever”
use [16] or a direct question on medication use [17,21]
or when prescriptions were brought to the interview
[18]. On the other hand, Nielsen et al. [13] also found
low sensitivity for psycholeptics (38%) and especially
for hypnotics and sedatives (27%). Thus, the low sensi-
tivity in our study (29%) for the group of other psycho-
active medication might be due to the high proportion
of users of hypnotics and sedatives in our study sample.
Similar to our study, moderate overall agreement
(>0.50) for psycholeptics [13] (vs. psychoactive medica-
tion) and even better for antidepressants reporting
[12,13,16,17,22] has been shown by others.
In the present study, users of psychoactive medica-
tion showed lower sensitivity for diuretics than non-
users, but they reported the use of diuretics better
than the use of psychoactive medication. Also in
previous studies, the use of psychoactive medication
has been less accurately reported than other medica-
tions [9,11,13]. Interestingly, however, a lower sensi-
tivity in respect to psychoactive medication in this
study was linearly related to less severe psychiatric
problems (i.e. no work disability pension due to psy-
chiatric cause) and lower use of psychoactivemedication. One explanation may simply be that psy-
choactive medicines such as hypnotics are not used
as regularly as diuretics. One might just not feel that
occasional use is important enough to be mentioned
in a questionnaire or the medicine may not be used
at the moment or at all after purchase. Lin et al.
[32] found that 28% of patients discontinued their
antidepressant medication during the first month of
therapy and 44% by the third month of therapy.
Longer and regular use may increase recall or reduce
self-perceived shame or unwillingness to report the
use [10,11,16,33].
In Finland the use of antidepressants doubled be-
tween 1999–2009 [34], which might decrease the un-
willingness to report use of medication. However,
our study subjects increased less their use of antide-
pressants between 1999–2009 and the sensitivity of
self-report of antidepressants in 2009 was similar to
that in 1999 (data not shown). It seems that regular
use of antidepressants and/or long-term severe men-
tal illness (as indicated by work disability pension)
are the most important correlates of sufficient self-
report.
In general, several factors may affect the agreement
between self-reports and register-based data. Obesity
has been previously positively associated with agree-
ment when self-reports have been compared to med-
ical records [12], but higher BMI is associated also
with depression [35]. Thus, after including the
amount of antidepressants or psychoactive medica-
tion (model 2), the significance of BMI in respect to
sensitivity disappeared. Lower income [5,16] and
education level [3,5,10,22] have been associated with
poorer agreement, but Sjahid et al. [6] found no dif-
ferences according to educational or socio-economic
status. Homogeneity of our cohort may have played
a role in some of the factors. In our female sample,
only a small number of women had a higher educa-
tion, which may have contributed to the non-
significance of education. Older age has [11,36] or
has not [6] been associated with decreased validity
of self-reports, while narrow age window in our
study (57–68 years) might explain the found minimal
age effect. In this study, being single was associated
with the highest sensitivity in reporting psychoactive
medication use, while in another Finnish cohort born
in 1966 [22] the same was true for the married sub-
jects. Lastly, even if Van den Brandt et al. [11] study
suggested a decrease in recall along with increasing
number of prescribed medications, in our study
higher number of any prescribed medication cur-
rently in use was associated with better sensitivity.
Stability of disease status indicated by history of
work disability pension and amount of psychoactive
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ant positive determinants of agreement than putative
(negative) effects of mental disease or its medication.
The strengths of this study include a large population-
based cohort, high response rate and utilization of the
National prescription register, which has a coverage of
97% and ability to detect also slight (i.e. irregular) use
[31]. The narrow age range increased the homogeneity
of the sample, but provides data on important period
around retirement. Lastly, our results apply to postmen-
opausal women, a risk group for depression, and a base
for future growing elderly population. Our method of
asking current use of any prescribed medications may
give lower agreement when compared to the results
obtained by never-ever -type questions. Since the pre-
scription register as a reference indicates only
the medication purchased and not the actual use, it pos-
sesses a possibility to non-agreement, but this inaccuracy
was minimized by checking also purchase of medication
after enquiry.
Conclusions
Less than half of the women reported their use of
any psychoactive medication and just over half their
use of antidepressants compared to register-based
data on purchased medication. The sensitivity of
self-report increased considerably with higher use,
with a history of work disability pension due to psy-
chiatric cause or when occasional use was excluded.
In conclusion, for research purposes, self-reported
current medication use seems in general to be a suf-
ficient indicator of regular use of antidepressants or
in respect of use of any psychoactive medication, for
those with severe psychiatric disease. However, pre-
scription register data is more reliable for those
using these medications irregularly and with less se-
vere mental disorders.
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